Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca - PubMed (original) (raw)
Determination of N,N-dimethyltryptamine and beta-carboline alkaloids in human plasma following oral administration of Ayahuasca
Mercedes Yritia et al. J Chromatogr B Analyt Technol Biomed Life Sci. 2002.
Abstract
Ayahuasca is a South American psychotropic beverage prepared from plants native to the Amazon River Basin. It combines the hallucinogenic agent and 5-HT(2A/2C) agonist N,N-dimethyltryptamine (DMT) with beta-carboline alkaloids showing monoamine oxidase-inhibiting properties. In the present paper, an analytical methodology for the plasma quantification of the four main alkaloids present in ayahuasca plus two major metabolites is described. DMT was extracted by liquid-liquid extraction with n-pentane and quantified by gas chromatography with nitrogen-phosphorus detection. Recovery was 74%, and precision and accuracy were better than 9.9%. The limit of quantification (LOQ) was 1.6 ng/ml. Harmine, harmaline, and tetrahydroharmine (THH), the three main beta-carbolines present in ayahuasca, and harmol and harmalol (O-demethylation metabolites of harmine and harmaline, respectively) were measured in plasma by means of high-performance liquid chromatography (HPLC) with fluorescence detection. Sample preparation was accomplished by solid-phase extraction, which facilitated the automation of the process. All five beta-carbolines were measured using a single detector by switching wavelengths. Separation of harmol and harmalol required only slight changes in the chromatographic conditions. Method validation demonstrated good recoveries, above 87%, and accuracy and precision better than 13.4%. The LOQ was 0.5 ng/ml for harmine, 0.3 ng/ml for harmaline, 1.0 ng/ml for THH, and 0.3 ng/ml for harmol and harmalol. Good linearity was observed in the concentration ranges evaluated for DMT (2.5-50 ng/ml) and the beta-carbolines (0.3-100 ng/ml). The gas chromatography and HPLC methods described allowed adequate characterization of the pharmacokinetics of the four main alkaloids present in ayahuasca, and also of two major beta-carboline metabolites not previously described in the literature.
Similar articles
- Metabolism and disposition of N,N-dimethyltryptamine and harmala alkaloids after oral administration of ayahuasca.
Riba J, McIlhenny EH, Valle M, Bouso JC, Barker SA. Riba J, et al. Drug Test Anal. 2012 Jul-Aug;4(7-8):610-6. doi: 10.1002/dta.1344. Epub 2012 Apr 19. Drug Test Anal. 2012. PMID: 22514127 - Quantitation of N,N-dimethyltryptamine and harmala alkaloids in human plasma after oral dosing with ayahuasca.
Callaway JC, Raymon LP, Hearn WL, McKenna DJ, Grob CS, Brito GS, Mash DC. Callaway JC, et al. J Anal Toxicol. 1996 Oct;20(6):492-7. doi: 10.1093/jat/20.6.492. J Anal Toxicol. 1996. PMID: 8889686 - Gas chromatographic analysis of dimethyltryptamine and beta-carboline alkaloids in ayahuasca, an Amazonian psychoactive plant beverage.
Pires AP, De Oliveira CD, Moura S, Dörr FA, Silva WA, Yonamine M. Pires AP, et al. Phytochem Anal. 2009 Mar-Apr;20(2):149-53. doi: 10.1002/pca.1110. Phytochem Anal. 2009. PMID: 19140116 - Effects of Ayahuasca and its Alkaloids on Drug Dependence: A Systematic Literature Review of Quantitative Studies in Animals and Humans.
Nunes AA, Dos Santos RG, Osório FL, Sanches RF, Crippa JA, Hallak JE. Nunes AA, et al. J Psychoactive Drugs. 2016 Jul-Aug;48(3):195-205. doi: 10.1080/02791072.2016.1188225. Epub 2016 May 26. J Psychoactive Drugs. 2016. PMID: 27230395 Review. - Neurobiological research on N,N-dimethyltryptamine (DMT) and its potentiation by monoamine oxidase (MAO) inhibition: from ayahuasca to synthetic combinations of DMT and MAO inhibitors.
Egger K, Aicher HD, Cumming P, Scheidegger M. Egger K, et al. Cell Mol Life Sci. 2024 Sep 10;81(1):395. doi: 10.1007/s00018-024-05353-6. Cell Mol Life Sci. 2024. PMID: 39254764 Free PMC article. Review.
Cited by
- Pharmacokinetics of N,N-dimethyltryptamine in Humans.
Good M, Joel Z, Benway T, Routledge C, Timmermann C, Erritzoe D, Weaver R, Allen G, Hughes C, Topping H, Bowman A, James E. Good M, et al. Eur J Drug Metab Pharmacokinet. 2023 May;48(3):311-327. doi: 10.1007/s13318-023-00822-y. Epub 2023 Apr 22. Eur J Drug Metab Pharmacokinet. 2023. PMID: 37086340 Free PMC article. Clinical Trial. - Administration of N,N-dimethyltryptamine (DMT) in psychedelic therapeutics and research and the study of endogenous DMT.
Barker SA. Barker SA. Psychopharmacology (Berl). 2022 Jun;239(6):1749-1763. doi: 10.1007/s00213-022-06065-0. Epub 2022 Jan 22. Psychopharmacology (Berl). 2022. PMID: 35064294 Free PMC article. Review. - Psychoactive Substances of Natural Origin: Toxicological Aspects, Therapeutic Properties and Analysis in Biological Samples.
Gonçalves J, Luís Â, Gallardo E, Duarte AP. Gonçalves J, et al. Molecules. 2021 Mar 5;26(5):1397. doi: 10.3390/molecules26051397. Molecules. 2021. PMID: 33807728 Free PMC article. Review. - Toxicokinetics and Toxicodynamics of Ayahuasca Alkaloids N,_N_-Dimethyltryptamine (DMT), Harmine, Harmaline and Tetrahydroharmine: Clinical and Forensic Impact.
Brito-da-Costa AM, Dias-da-Silva D, Gomes NGM, Dinis-Oliveira RJ, Madureira-Carvalho Á. Brito-da-Costa AM, et al. Pharmaceuticals (Basel). 2020 Oct 23;13(11):334. doi: 10.3390/ph13110334. Pharmaceuticals (Basel). 2020. PMID: 33114119 Free PMC article. Review. - The pharmacological interaction of compounds in ayahuasca: a systematic review.
Ruffell S, Netzband N, Bird C, Young AH, Juruena MF. Ruffell S, et al. Braz J Psychiatry. 2020 Nov-Dec;42(6):646-656. doi: 10.1590/1516-4446-2020-0884. Braz J Psychiatry. 2020. PMID: 32638916 Free PMC article.